Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

BACKGROUND: Evidence from clinical trials suggests that the addition of bevacizumab to chemotherapy in the first-line treatment of patients with HER2-negative metastatic breast cancer improves progression-free survival (PFS) but not overall survival (OS). However, a retrospective analysis of real-wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Petitjean, Audrey, Smith-Palmer, Jayne, Valentine, William, Tehard, Bertrand, Roze, Stephané
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371553/
https://www.ncbi.nlm.nih.gov/pubmed/30744578
http://dx.doi.org/10.1186/s12885-019-5335-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371553/
https://www.ncbi.nlm.nih.gov/pubmed/30744578
http://dx.doi.org/10.1186/s12885-019-5335-8

Ejemplares similares